MERCK & CO., INC.

(MRK)
  Report
Delayed Nyse  -  05/23 04:04:12 pm EDT
93.83 USD   +0.30%
10:18aSeagen Sees Positive Topline Data From Study of Tukysa With Trastuzumab in HER2-Positive Metastatic Colorectal Cancer
MT
09:15aMerck Receives Positive EU CHMP Opinion for KEYTRUDA (pembrolizumab) as Adjuvant Treatment for Adult and Adolescent (12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection
AQ
05:49aMerck & Co. Plans $470 Million Investment In Manufacturing Facilities In Ireland
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Evolution of the average Target Price on MERCK & CO., INC.
Target Price consensus revisions : last 18 months
Recommendations (Chart) MERCK & CO., INC.
Analyst Recommendations on MERCK & CO., INC.
05/17Berenberg Bank Adjusts Merck's Price Target to $95 From $87, Maintains Hold Rating
MT
04/29Morgan Stanley Adjusts Merck & Co.'s Price Target to $87 from $80, Keeps Equalweight Ratin..
MT
04/29Goldman Sachs Adjusts Price Target for Merck & Company to $105 From $101, Maintains Buy Ra..
MT
04/29JPMorgan Adjusts Price Target for Merck & Company to $100 From $95, Maintains Overweight R..
MT
04/29Wells Fargo Raises Merck & Company's Price Target to $105 From $90, Reiterates Overweight ..
MT
04/29SVB Leerink Adjusts Merck & Co.'s Price Target to $102 from $97, Keeps Outperform Rating
MT
04/21SVB Leerink Adjusts Merck & Co.'s Price Target to $97 From $100, Keeps Outperform Rating
MT
More recommendations
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Last Close Price 93,55 $
Average target price 96,04 $
Spread / Average Target 2,67%
High Price Target 115,00 $
Spread / Highest target 22,9%
Low Price Target 76,00 $
Spread / Lowest Target -18,8%
Consensus detail
Consensus revision (last 18 months)